Watershed Informatics Exhibit at RESI JPM San Francisco

Madeline-Kelly
Madeline Kelly
Interview with Madeline Kelly, Head of Sales, Watershed Informatics

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti
Caitlin Dolegowski

Watershed Informatics’ intuitive Data Lab platform empowers our clients to design, execute, and iterate their own sequencing analyses, shortening time between iterations and enabling more efficient and effective experimentation. They expedite and multiply the development of targeted, breakthrough therapies and diagnostics. Watershed returns to RESI this January as an exhibitor. In the following interview, Watershed’s Head of Sales, Madeline Kelly, provides insight on how Watershed came to be, their technology, team, and target customer.

Caiti Dolegowski (CD): Please introduce us to Watershed. Tell us about your technology and platform.

Madeline Kelly (MK): Watershed Informatics is the first fully verticalized bio-IT platform. Our Cloud Data Lab enables life sciences organizations of any size to perform mission-critical bioinformatics analyses (such as bulk, single-cell, and spatial transcriptomics; WGS, proteomics, protein folding, AI/ML etc.) at an order of magnitude less cost and complexity than existing solutions. With purpose-built infrastructure specifically optimized for catalyzing the life sciences development pipeline, our product enables biologists to analyze their own data and bioinformaticians to rapidly prototype and deploy bespoke analytic workflows across an organization.

CD: Tell us about Watershed’s team?

MK: We are a team of expert bioinformaticians, software engineers, and biologists inspired by one mission: to enable all scientists – regardless of their programming capabilities – to leverage multi-modal data for building better drugs faster.

CD: Watershed’s Cloud Data lab can be traced to a conversation between co-founders, Jonathan Wang and Mark Kalinich. What was the conversation and how do they complement each other?

MK: Jonathan and Mark have been friends since their first day of MIT – they were actually next-door neighbors freshman year! As a software engineer, Jonathan has always been fascinated by high-performance computational infrastructure. He co-founded an algorithmic trading firm while still a student at MIT. While there, he perfected the tech stack required to democratize access to petabyte-scale ML infrastructure for software engineers and financial researchers alike. Mark is a Harvard-trained physician-scientist with nearly 15 years of translational research experience across diagnostics and therapeutics development. His mission is to improve the lives of patients by developing and deploying the enabling technologies required to bring therapeutics out of the laboratory and into the clinic. Their expertise and passions directly intersect at the problem Watershed solves: uncorking the bottleneck for biotech and pharma’s data-intensive research efforts.

CD: Who is your target customer? And what are the different offerings you provide your clients?

MK: Our target customers want to successfully and efficiently analyze their big biology data (most often -omics, but also protein folding and high content imaging) without the massive overhead currently required. (To learn more about what we mean by overhead, download our white paper). With our no-code / low-code / high-code interoperability, our platform is useful to biologists and bioinformaticians alike.

CD: Do you have a process for assessing your clients’ needs? How does that work?

MK: Watershed employs a highly consultative sales and onboarding process. We thoroughly assess the needs of our customers by learning about their workflow, analysis, and visualization needs. Our team of bioinformaticians are ready to assist our clients from day 1.

CD: Could you give us examples of current Watershed clients and how they’ve utilized your informatics?

MK: Some of our clients include SalioGen, Cellino, SynDevRx, Rejuvenate Bio, Rarebase, Revitope, and a few stealth biotech startups. Our customers’ most common request is processing next-generation sequencing data across a variety of workflows (bulk, single-cell, and spatial RNAseq; whole genome and whole exome sequencing, bulk and single-cell ATACseq, immune repertoire sequencing, CRISPR-based analyses, custom sequencing libraries, etc) and technologies (Illumina, ONT, PacBio). In addition to other data-intensive workflows (metabolomics, proteomics, high-content imaging, protein-folding) and publicly available datasets (TCGA, CCLE, GTex, UKBB), our platform has been purpose-built to overlay advanced AI/ML techniques on these data, including deep learning, generative AI, structure-based learning models, and NLP, among others.

CD: We’re thrilled to Watershed back as an exhibitor at RESI JPM San Francisco! What would you like our RESI attendees to know about Watershed

MK: We are excited to join RESI JPM San Francisco as first-time attendees! We want to meet as many of you as possible, so swing by our booth to check out our platform and enter for a chance to win 1 free month of Watershed’s Cloud Data Lab (details available at the conference). See you there!

RESI-SF-2023-Banner-1100-wide

RESI JPM San Francisco 2023 Investor Panelists

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

RESI JPM San Francisco 2023 is fast approaching. The Life Science Nation (LSN) team has been busy putting together a program of 8 panels that provides latest insights on early-stage life science and healthcare.

We are excited to have invited a diverse lineup of panelists from different types of investment groups, including Big Pharma, corporate VCs, medtech strategics, traditional VCs, angels and family offices, to share their strategies and approaches on early-stage investment, perspectives on industry landscape, startup ecosystem and more. As a global conference, we are also delighted to have many international investors and cross-border investment groups to join and contribute to these dynamic discussions. The goal of RESI panels is to facilitate constructive conversations between investors and fundraising CEOs, and provide tactical advice on how companies can raise capital and acquire partnerships effectively. These must-see panels are great opportunities for founders and CEOs to engage with investors and kick off their fundraising journey of 2023.

Join the panelists below at RESI JPM San Francisco:


Mel Barsky
Director of Business Development
Centre for Aging + Brain Health Innovation (CABHI)

Lana Caron
Innovation Lead
Philips Ventures
Bruce Cohen
Bruce Cohen
Venture Partner
Xeraya Capital
Matt Deschner
Matt Deschner
Business Development & Licensing – Surgical Innovations
Medtronic

Gini Deshpande
Partner of Cathay Capital
Niels Emmerich
Niels Emmerich
Vice President, Global Head Search and Evaluation
AbbVie
Xi Fang
Xi Fang
Managing Partner
Button Capital
Jon Friedland
Jon Friedland
Managing Director, Ventures
Cleveland Clinic Ventures
Amit Garg
Amit Garg
Managing Partner
Tau Ventures
Lana Ghanem
Lana Ghanem
Managing Director
Hikma Ventures
Tom Gibbs
Tom Gibbs
Director
Debiopharm Innovation Fund
Gita Gupta
Gita Gupta
Partner
NextStep Ventures
Duncan Huston-Paterson
Duncan Huston-Paterson
Senior Manager, Business Development
Amgen
Kristin King
Kristin King
Member
Boston Harbor Angels
Fiona Mack
Fiona Mack
VP, Head of CoLaborator
Bayer
Nola Masterson
Nola Masterson
Managing Director
Science Futures
Andrew Meadow
Andrew Meadow
General Partner
Health Innovation Capital
Tamir Meiri
Tamir Meiri
Senior Manager, Venture Investments
Johnson & Johnson Innovation
Ole Mensching
Ole Mensching
Co-Founder and General Partner
Apollo Health Ventures
Ravi Mistry
Ravi Mistry
Angel Investor
John Parker
John Parker
Founder & Managing Director
Springhood Ventures
Armin Rump
Armin Rump
Manager, Global Business Development
Otsuka Pharmaceutical
Akhil Saklecha
Akhil Saklecha
Chief Scientific Officer, Acute Care
Danaher Corporation
Yoke Sin
Yoke Sin
Managing Partner
iGlobe Partners
Lesley Stolz
Lesley Stolz
Regional Vice President, Early Innovation Partnering
Johnson & Johnson Innovation
Sally Wang
Sally Wang
Venture Partner
Viva BioInnovator
Oscar Zhang
Oscar Zhang
Principal
Qiming Venture Partners
Lu Zhang
Lu Zhang
Managing Partner
Fusion Fund
Cheryl Zimberlin
Cheryl Zimberlin
Investment Director
M Ventures

RESI-SF-2023-Banner-1100-wide

Crafting the Perfect Message

By Karen Deyo, VP of Product, Israel BD, LSN

You’ve registered for a partnering conference.

You’ve filled out a profile in the partnering system detailing who you are and what your company does.

You’ve researched the investors in attendance and built a list of targets to book meetings with.

You hit “Request a Meeting” and freeze.

What message will increase your chances of the investor accepting the request?

Partnering is an involved process with multiple steps that must be taken to ensure optimal results. These steps often require major time investment, and we forget that, even after the hours we’ve poured into the process, none of it matters without a compelling message to pique the interest of a potential partner. Furthermore, this is a process that requires a plan for following up, since, as with any outreach, it will likely take more than one message to the investors to receive a response. These messages should be clear and concise, no more than a paragraph, highlighting your company and what makes it unique.

Life Science Nation (LSN) has developed and consolidated your partnering outreach into four separate messages:

  1. Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
  2. Company tagline (5-6 words explaining who you are and what you do)
  3. Elevator pitch (1-3 sentences describing the company and tech)
  4. Technology differentiation, product innovation, or market position
  5. Raise and milestone information
  6. Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
  7. Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development? What makes your people special?
  8. Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later.

It should go without saying that the perfect message is meaningless without a well-researched and formulated target list and marketing collateral at the ready. Think of the perfect message like how an athlete approaches the arena on game day. It’s the starting shot of a long and exciting process. It won’t replace the training and conditioning that got you to game day, but it’ll ensure you’re off with a competitive edge.

Hot Investor Mandate: Leading VC in Europe Invests Up to $20M in Early and Growth-Stage Life Science Companies, With Early Clinical Data Validation in Place

A leading European Venture Capital firm investing in early-and growth stage life science companies is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totaling EUR 1.0 billion, the firm has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, the firm has invested in over 50 innovative life science companies. Initial ticket size ranges between EUR 5-10 million and up to EUR 20 million over the life of the investment.

The firm invest mainly in Europe and selectively in US across five broad areas:  Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology and R&D tools. Regarding therapeutics, the firm focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms, or with early clinical data. In the other fields, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product and have some early market traction in the single million digit range.

The firm typically requests a board seat and looks for a strong and experienced management team while supporting highly talented entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Venture Firm Seeks Medical Device & Diagnostics Companies, Most Interested in 510k Technologies

A Venture Capital company based in USA has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has long term relationships with several Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West coast of the US, although they are also open to review opportunities in North America.

The firm is looking for seed and early-stage medical device and diagnostic companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: PE/VC Firm in Asia Invests $5-15M in All Life Science & Healthcare Sectors and Open to Global Opportunities

A Life Science focused private equity and venture capital firm based in Asia manages an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Actively Seeking Innovative Medical Devices in Cardiovascular and Neurovascular Diseases, Focusing on USA, Europe, Israel

A venture capital investment firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €4-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.